Somapacitan LA is a Recombinant Protein owned by Novo Nordisk, and is involved in 21 clinical trials, of which 14 were completed, 5 are ongoing, and 2 are planned.

Somapacitan (NNC0195-0092) works as hormone replacement therapy. Human growth hormone (hGH) binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR activating a variety of signaling molecules such as JAK2 tyrosine kinase. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately leads to changes in growth and metabolism.

The revenue for Somapacitan LA is expected to reach a total of $5.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Somapacitan LA NPV Report.

Somapacitan LA is originated and owned by Novo Nordisk.

Somapacitan LA Overview

Somapacitan (Sogroya) is a human growth hormone analog. It is formulated as solution for subcutaneous route of administration. Sogroya is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (GHD).

Somapacitan (NNC0195-0092) is under development for the treatment of growth hormone deficiency, born small for gestational age,Turner Syndrome, Noonan Syndrome, and idiopathic short stature. The drug candidate is administered subcutaneously as a solution. It acts by targeting somatotropin receptor. It is a long-acting albumin-binding growth hormone derivative.

Novo Nordisk Overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. the company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

The company reported revenues of (Danish Krone) DKK140,800 million for the fiscal year ended December 2021 (FY2021), an increase of 10.9% over FY2020. In FY2021, the company’s operating margin was 41.7%, compared to an operating margin of 42.6% in FY2020. In FY2021, the company recorded a net margin of 33.9%, compared to a net margin of 33.2% in FY2020. The company reported revenues of DKK45,566 million for the third quarter ended September 2022, an increase of 10.4% over the previous quarter.

Quick View – Somapacitan LA

Report Segments
  • Innovator (NME)
Drug Name
  • Somapacitan LA
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Genetic Disorders
  • Hormonal Disorders
  • Women’s Health
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.